CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A
Researchers at Children's Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in […]
NEWTON, Mass, Dec. 01, 2018 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line […]Hematology
Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting